Taiwan RUO immunoassay market is expected to grow at a CAGR of 11.88% from 2025 to 2030.
Taiwan is an aging society, and the elderly population (aged over 65) has doubled in the last 10 years, turning into an aged society, and the percentage is expected to surpass 20% by 2025. In response, the government offers various strategic programs for this age group as it is more prone to different types of diseases. The rise in chronic ailments such as cancer and diabetes are on the rise. The number of people with diabetes for the age group (20-79 y) was estimated at 2,457.2 (in 1,000s) in 2021, 2,979.4 in 2030, and 3,030.7 in 2045. The cancer incidence was 121,762 in 2021, with 51,656 mortalities.
As the technology continues to develop, RUO immunoassays are likely to become an even more valuable tool for healthcare providers in Taiwan. Firstep Bioresearch, Inc. is a leading manufacturer of Diagnostic Instruments and Test Kits. The company has emerged as a prominent provider of contract manufacturing services (OEM/ODM) for in vitro diagnostic products. It specializes in producing high-quality reagents and medical devices using the Lateral Flow Immunochromatographic Technique and develops a range of Antigen and Antibody Rapid Tests. It is committed to advancing innovative technologies through collaborations with renowned engineering universities.
The grant amounts to KRW General Biologicals Corporation (GBC) is the first company to develop the first In-vitro Diagnostic (IVD) HBV kit using RIA-based technology as part of Taiwan's nationwide Liver Disease Prevention Program, and has a range of offerings from RIA, ELISA (Immunoassay), and Real-Time PCR (Molecular) to CTC (Circulating Tumor Cell). With an expanding range of products including Tumor markers, Fertility, Torch, and Thyroid tests, GBC now has two R&D Centers (Hsin Chu, Taiwan, and San Diego, USA).
In July 2023, the company unveiled two CellBio™ circulating tumor cell (CTC) cancer detection products. These CTC detection systems are viewed globally at the forefront of science and are used for early detection, treatment validation, and therapy monitoring with rapid, accessible, and affordable diagnostic solutions. Its GB SARS-CoV-2 Ab is a semi-quantitative ELISA kit designed to detect antibodies against the SARS-CoV-2 virus (anti-SARS-CoV-2) in human serum or plasma.
Several major companies are developing innovative products and collaborating with universities and other research institutions. For example, in August 2023, Elixiron collaborated with Yang-Ming University to co-develop innovative immunotherapy technology for head and neck cancer, which involves a novel drug that combines a tumor macrophage-targeting antibody with an interleukin-10 fusion protein. Multi-Plex Immunoassay (MPI) offered by the Institute of Biomedical Sciences, Academia Sinica is a technology for simultaneous quantification of analytes in serum/plasma and culture supernatants, serving as a valuable tool in disease mechanistic studies and biomarker discovery. It provides cytokine and chemokine analysis in the field of immunology using fully validated detection panels.
Taiwan RUO Immunoassay Market Segmentation
By Product Type
By Sample Type
By Application
By End-User